We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
416 hedge funds and large institutions have $8.21B invested in Royalty Pharma in 2024 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 162 increasing their positions, 135 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
466% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $3.2M
54% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 50
20% more repeat investments, than reductions
Existing positions increased: 162 | Existing positions reduced: 135
5% more funds holding
Funds holding: 395 → 416 (+21)
2.54% more ownership
Funds ownership: 69.88% → 72.43% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
7% less capital invested
Capital invested by funds: $8.86B → $8.21B (-$651M)
Holders
416
Holders Change
+21
Holders Change %
+5.32%
% of All Funds
5.48%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
77
Increased
162
Reduced
135
Closed
50
Calls
$18.1M
Puts
$3.2M
Net Calls
+$14.9M
Net Calls Change
-$4.48M
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$134M |
| 2 |
BlackRock
New York
|
+$83.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$76.8M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$43.6M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$32.9M |
Top Sellers
| 1 |
SCM
Suvretta Capital Management
New York
|
-$52.8M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$52.7M |
| 3 |
Millennium Management
New York
|
-$51.1M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$45.8M |
| 5 |
Morgan Stanley
New York
|
-$41M |
